HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- ...

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...

This study investigates the potential of amygdalin, a natural compound found in almonds, peaches, and apples, as a therapeutic agent for HER2-positive ...

Katie Thurston, the former Bachelorette alum, is facing stage 4 breast cancer with honesty and courage. On July 3, she shared ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

A new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...